Conditions: Lymphoma
Intervention Type: Biological
Intervention Names
The following are clinical trials from the Healia Clinical Trials Information Database related to "Lymphoma" that are researching the effect of "Biological" interventions organized by the name of the intervention.
- Lymphoma - Biological - rituximab (23 documents)
- Lymphoma - Biological - sargramostim (8 documents)
- Lymphoma - Biological - apolizumab (5 documents)
- Lymphoma - Biological - denileukin diftitox (4 documents)
- Lymphoma - Biological - recombinant interleukin-12 (4 documents)
- Lymphoma - Biological - LMB-2 immunotoxin (3 documents)
- Lymphoma - Biological - aldesleukin (3 documents)
- Lymphoma - Biological - alemtuzumab (3 documents)
- Lymphoma - Biological - epoetin alfa (3 documents)
- Lymphoma - Biological - aflibercept (2 documents)
- Lymphoma - Biological - allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes (2 documents)
- Lymphoma - Biological - daclizumab (2 documents)
- Lymphoma - Biological - epratuzumab (2 documents)
- Lymphoma - Biological - ipilimumab (2 documents)
- Lymphoma - Biological - recombinant interferon alfa (2 documents)
- Lymphoma - Biological - therapeutic allogeneic lymphocytes (2 documents)
- Lymphoma - Biological - 18F-FLT (1 documents)
- Lymphoma - Biological - AS03-adjuvanted H1N1 pandemic influenza vaccine (1 documents)
- Lymphoma - Biological - AlloStim (1 documents)
- Lymphoma - Biological - Autologous AdE1- Latent Membrane Protein CTLs (1 documents)
- Lymphoma - Biological - Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS (1 documents)
- Lymphoma - Biological - B43-genistein immunoconjugate (1 documents)
- Lymphoma - Biological - Bevacizumab (1 documents)
- Lymphoma - Biological - DNA Vaccine (1 documents)
- Lymphoma - Biological - Donor lymphocyte preparation depleted of host functional alloreactive T-cells (1 documents)
- Lymphoma - Biological - Donor lymphocytes (1 documents)
- Lymphoma - Biological - EBV specific T cells (1 documents)
- Lymphoma - Biological - G-CSF (1 documents)
- Lymphoma - Biological - Genetically modified T cells (1 documents)
- Lymphoma - Biological - Hematopoietic Stem Cell Transplant (HSCT) (1 documents)
- Lymphoma - Biological - Id-KLH (1 documents)
- Lymphoma - Biological - LMB-2 (1 documents)
- Lymphoma - Biological - LMP2a-specific cytotoxic T-lymphocytes (1 documents)
- Lymphoma - Biological - NK Cell Infusion (1 documents)
- Lymphoma - Biological - NK-92 cells (1 documents)
- Lymphoma - Biological - NK-Cell Infusion (1 documents)
- Lymphoma - Biological - NK-DLI Infusions (1 documents)
- Lymphoma - Biological - Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus (1 documents)
- Lymphoma - Biological - Sargramostim (GM-CSF) (1 documents)
- Lymphoma - Biological - TGF-beta-resistant LMP-specific cytotoxic T-lymphocytes (1 documents)
- Lymphoma - Biological - Trivalent Baculovirus-expressed Influenza HA vaccine (1 documents)
- Lymphoma - Biological - Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning (1 documents)
- Lymphoma - Biological - Unmanipulated UCB Unit (1 documents)
- Lymphoma - Biological - anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (1 documents)
- Lymphoma - Biological - autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (1 documents)
- Lymphoma - Biological - autologous LMP1-/LMP2- specific cytotoxic T-lymphocytes (1 documents)
- Lymphoma - Biological - autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine (1 documents)
- Lymphoma - Biological - autologous tumor cell vaccine (1 documents)
- Lymphoma - Biological - bevacizumab (1 documents)
- Lymphoma - Biological - bleomycin sulfate (1 documents)
- Lymphoma - Biological - donor lymphocytes (1 documents)
- Lymphoma - Biological - etaracizumab (1 documents)
- Lymphoma - Biological - galiximab (1 documents)
- Lymphoma - Biological - helicobacter pylori vaccine (1 documents)
- Lymphoma - Biological - human myeloid progenitor cells (1 documents)
- Lymphoma - Biological - iratumumab (1 documents)
- Lymphoma - Biological - keyhole limpet hemocyanin (1 documents)
- Lymphoma - Biological - lumiliximab (1 documents)
- Lymphoma - Biological - monoclonal antibody E2.3 (1 documents)
- Lymphoma - Biological - monoclonal antibody HeFi-1 (1 documents)
- Lymphoma - Biological - monoclonal antibody mono-dgA-RFB4 (1 documents)
- Lymphoma - Biological - oblimersen sodium (1 documents)
- Lymphoma - Biological - ofatumumab (1 documents)
- Lymphoma - Biological - pegylated interferon alfa (1 documents)
- Lymphoma - Biological - peripheral blood lymphocyte therapy (1 documents)
- Lymphoma - Biological - recombinant human mannose-binding lectin (1 documents)
- Lymphoma - Biological - recombinant human stem cell factor (1 documents)
- Lymphoma - Biological - recombinant interleukin-11 (1 documents)
- Lymphoma - Biological - siplizumab (1 documents)
- Lymphoma - Biological - tetanus toxoid (1 documents)
- Lymphoma - Biological - tumor cell-based vaccine therapy (1 documents)
- Lymphoma - Biological - veltuzumab (1 documents)
- Lymphoma - Biological - visilizumab (1 documents)
